Evolocumab

Papers on evolocumab

86 papers40 new in 30 days

Wednesday, November 18

Monday, November 16

Thursday, November 12

Tuesday, November 10

Monday, November 9

Journal of the American College of Cardiology

Evolocumab cut combined heart and stroke risk in kidney impairment

Evolocumab reduced the relative risk of coronary heart disease death, heart attack or stroke by 39% versus placebo in people with reduced kidney function.Evolocumab reduced the relative risk of coronary heart disease death, heart attack or stroke by 39% versus placebo in people with reduced kidney function.

Artery cross-sections beneath kidneys contrast an open passage with sparse cholesterol particles against a clot-blocked passage with dense particles.
Randomized trial · 2,140 peopleEvolocumab
AHA Scientific Sessions 2026 Abstract

Evolocumab linked to fewer deaths in high-risk adults

Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.

Artery cross-sections contain plaque and contrasting sparse and dense cholesterol particles, surrounded by small upright, faceless people.
Cohort studyEvolocumab

Saturday, November 7

AHA Scientific Sessions 2026 Abstract

Evolocumab reduced cardiovascular risk in kidney disease

Over a median 4.6 years, evolocumab reduced the combined relative risk of coronary heart disease death, heart attack or stroke from a blocked artery by 39% versus…Over a median 4.6 years, evolocumab reduced the combined relative risk of coronary heart disease death, heart attack or stroke from a blocked artery by 39% versus placebo.

Artery cutaways show sparse versus dense cholesterol particles and less versus more plaque, with kidneys above and an antibody beside them.
Randomized trial · 2,140 peopleEvolocumab
AHA Scientific Sessions 2026 Abstract

Evolocumab reduced first-stroke risk in high-risk patients

Estimated five-year stroke rates were 2.6% with evolocumab and 3.2% with placebo, a 24% relative reduction.Estimated five-year stroke rates were 2.6% with evolocumab and 3.2% with placebo, a 24% relative reduction.

Brain tissue with open arteries beside gray damaged tissue with a blocked vessel, with branching antibody shapes above.
Randomized trial · 12,257 peopleEvolocumab

Friday, November 6

Monday, November 2